IsoPlexis Past Earnings Performance
Past criteria checks 0/6
IsoPlexis's earnings have been declining at an average annual rate of -49.5%, while the Life Sciences industry saw earnings growing at 20.7% annually. Revenues have been growing at an average rate of 27% per year.
Key information
-49.5%
Earnings growth rate
35.2%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 27.0% |
| Return on equity | -256.9% |
| Net Margin | -632.4% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Revenue & Expenses Breakdown
How IsoPlexis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 17 | -106 | 73 | 23 |
| 30 Sep 22 | 19 | -98 | 74 | 25 |
| 30 Jun 22 | 19 | -104 | 77 | 26 |
| 31 Mar 22 | 19 | -102 | 76 | 24 |
| 31 Dec 21 | 17 | -92 | 64 | 21 |
| 30 Sep 21 | 15 | -76 | 51 | 18 |
| 30 Jun 21 | 14 | -59 | 40 | 15 |
| 31 Mar 21 | 12 | -41 | 29 | 12 |
| 31 Dec 20 | 10 | -29 | 22 | 11 |
| 31 Dec 19 | 8 | -15 | 12 | 10 |
Quality Earnings: ISO is currently unprofitable.
Growing Profit Margin: ISO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ISO's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ISO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ISO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-11.4%).
Return on Equity
High ROE: ISO has a negative Return on Equity (-256.86%), as it is currently unprofitable.